|
Amylin Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Amylin Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize potential drug candidates for the treatment of diabetes, obesity and cardiovascular disease. The Group has two approved products, BYETTA(R) (exenatide) injection, and SYMLIN(R) (pramlintide acetate) injection, both of which were commercially launched in the United States in 2005. BYETTA is the first and only approved medicine in a new class of compounds called incretin mimetics. SYMLIN is the first and only approved medicine in a new class of compounds called amylinomimetics. The Group has a global development and commercialization agreement for exenatide, including BYETTA and any sustained-release formulations of BYETTA, including exenatide LAR, with Eli Lilly & Company.
Competitor Analysis
This analysis compares Amylin Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
